NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

HLUNB.DK

42.86

+2.68%↑

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

HLUNB.DK

42.86

+2.68%↑

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

HLUNB.DK

42.86

+2.68%↑

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

HLUNB.DK

42.86

+2.68%↑

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

HLUNB.DK

42.86

+2.68%↑

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

Search

Coloplast A-S (Class B)

Suletud

394.7 -0.58

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

390.6

Max

397.2

Põhinäitajad

By Trading Economics

Sissetulek

522M

1.4B

Müük

83M

7B

P/E

Sektori keskmine

22.883

67.147

Aktsiakasum

6.32

Dividenditootlus

5.69

Kasumimarginaal

19.835

Töötajad

16,983

EBITDA

309M

2.3B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+11.86% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

5.69%

2.36%

Järgmine tulemuste avaldamine

12. mai 2026

Järgmine dividendimakse kuupäev

20. mai 2026

Järgmine aktsia dividendi kuupäev (ex-date)

18. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-27B

91B

Eelmine avamishind

395.28

Eelmine sulgemishind

394.7

Coloplast A-S (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2026, 23:53 UTC

Tulu

Naver Posts Weaker First-Quarter Earnings

29. apr 2026, 23:41 UTC

Kuumad aktsiad

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29. apr 2026, 23:55 UTC

Tulu

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29. apr 2026, 23:54 UTC

Tulu

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29. apr 2026, 23:52 UTC

Tulu

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29. apr 2026, 23:51 UTC

Tulu

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29. apr 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29. apr 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29. apr 2026, 23:22 UTC

Tulu

China Longyuan 1Q Net CNY1.70B, Down 14%

29. apr 2026, 23:22 UTC

Tulu

China Longyuan: Power Generation Down 2.9% as of End-March

29. apr 2026, 23:20 UTC

Tulu

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29. apr 2026, 23:20 UTC

Tulu

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Loss Narrows>000002.SZ

29. apr 2026, 23:18 UTC

Tulu

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29. apr 2026, 23:17 UTC

Tulu

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29. apr 2026, 23:15 UTC

Tulu

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29. apr 2026, 23:15 UTC

Tulu

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29. apr 2026, 23:13 UTC

Tulu

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29. apr 2026, 23:12 UTC

Tulu

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29. apr 2026, 23:11 UTC

Tulu

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29. apr 2026, 23:11 UTC

Tulu

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29. apr 2026, 23:04 UTC

Tulu

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29. apr 2026, 23:04 UTC

Tulu

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Võrdlus sarnastega

Hinnamuutus

Coloplast A-S (Class B) Prognoos

Hinnasiht

By TipRanks

11.86% tõus

12 kuu keskmine prognoos

Keskmine 901.38 DKK  11.86%

Kõrge 1,056 DKK

Madal 720 DKK

Põhineb 8 Wall Streeti analüütiku instrumendi Coloplast A-S (Class B) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

2

Osta

4

Hoia

2

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat